RedHill Biopharma Ltd.

RDHL

Healthcare|Drug Manufacturers - Specialty & Generic|IL

$0.43

+0.00 (+0.45%)

Cash / Share

$2.86

Clinical Trials (20)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT01980095 ERADICATE Hp - Treating Helicobacter Pylori With RHB-105	Dyspepsia, Helicobacter Pylori Infection	P3	Completed	119	RCT, Double-blind	RHB-105, Placebo
NCT04616924 RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease	Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis	P3	Terminated	12	RCT, Double-blind	RHB-204, Placebo
NCT04467840 Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia	COVID-19, Lung Infection	P2P3	Completed	475	RCT, Double-blind	Opaganib, Placebo
NCT03009396 Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease	Crohn Disease	P3	Completed	54	Open-label	RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
NCT02246439 BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis	Gastroenteritis, Gastritis	P3	Completed	330	RCT, Double-blind	RHB-102, Placebo Oral Tablet
NCT03198507 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator	Helicobacter Pylori Infection, Dyspepsia	P3	Completed	455	RCT, Double-blind	RHB-105, Active Comparator
NCT01951326 Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease	Crohn's Disease	P3	Completed	331	RCT, Double-blind	RHB-104, Placebo
NCT04723537 Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease	Covid19	P2P3	Terminated	61	RCT, Double-blind	Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo, Part B: Upamostat 200 or 400 mg
NCT02229981 Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma	Diffuse Large B Cell Lymphoma, Kaposi Sarcoma	P1P2	Withdrawn	—	Open-label	ABC294640
NCT02757326 ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma	Multiple Myeloma	P1P2	Terminated	13	Open-label	Opaganib
NCT03377179 A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma	Cholangiocarcinoma, Cholangiocarcinoma Non-resectable	P2	Completed	65	Open-label	ABC294640, Hydroxychloroquine Sulfate 200 MG
NCT04414618 A Study of Opaganib in Coronavirus Disease 2019 Pneumonia	Coronavirus Infections	P2	Completed	42	RCT, Double-blind	Opaganib, Placebo
NCT01717664 Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)	Relapsing Remitting Multiple Sclerosis	P2	Completed	18	Open-label	RHB-104
NCT04026984 Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years	Traveler's Diarrhea	P2	Unknown	142	RCT, Double-blind	Rifamycin SV-MMX, Placebo
NCT02757105 Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)	Irritable Bowel Syndrome With Diarrhea	P2	Completed	127	RCT, Double-blind	BEKINDA, Placebo
NCT05954286 PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19	SARS-CoV-2	P2	Completed	92	RCT, Double-blind	Upamostat, Placebo (PO)
NCT04027894 Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years	Traveler's Diarrhea	P2	Unknown	142	RCT, Double-blind	Rifamycin SV MMX, Placebo to Rifamycin SV-MMX
NCT04502069 Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen	COVID-19, Lung Infection	P1P2	Withdrawn	—	Open-label	Opaganib
NCT01488513 ABC294640 in Treating Patients With Advanced Solid Tumors	Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific	P1	Completed	22	Open-label	sphingosine kinase-2 inhibitor ABC294640
NCT03414489 Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)	Cholangiocarcinoma, Cholangiocarcinoma Non-resectable		NO_LONGER_AVAILABLE	—	—	ABC294640